Management of Guillain-Barré Syndrome in Children

First-Line Treatment Options

The American Academy of Neurology recommends IVIg (0.4 g/kg daily for 5 days) as the first-line therapy in children with GBS due to easier administration, better tolerability, and fewer complications compared to plasma exchange 1, 3
The 5-day IVIg regimen is preferred over a 2-day regimen, as treatment-related fluctuations were more frequent with the 2-day regimen (5/23 children) compared to the 5-day regimen (0/23 children) 3
Plasma exchange (200-250 ml/kg over 5 sessions) is an effective alternative when IVIg is contraindicated, not tolerated, or unavailable 1, 4
Corticosteroids alone are not recommended for GBS treatment as they have shown no significant benefit and may even have negative effects on outcomes 1, 2

Regular assessment of respiratory function is essential using the "20/30/40 rule": patient is at risk of respiratory failure if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1, 3
Monitor for single breath count (a single breath count of ≤19 predicts a requirement for mechanical ventilation), use of accessory respiratory muscles, and ability to cough 1, 3
Swallowing and coughing difficulties should be assessed to prevent aspiration 1, 3
Autonomic dysfunction should be monitored via electrocardiography, heart rate, blood pressure, and bowel/bladder function 1, 3

Approximately 40% of patients do not show improvement in the first 4 weeks following treatment, which doesn't necessarily indicate treatment ineffectiveness 1
Treatment-related fluctuations (TRFs) occur in 6-10% of patients within 2 months of initial improvement 1

Multidisciplinary supportive care is crucial and should include pain management, as pain is common in GBS patients 1, 3
Prevention of pressure ulcers, hospital-acquired infections (pneumonia, urinary tract infections), and deep vein thrombosis is essential 1, 3
Psychological support for anxiety, depression, and hallucinations which are frequent in GBS patients is crucial 1, 3
Patients should be monitored for cardiovascular complications, as up to two-thirds of deaths in GBS occur during the recovery phase due to cardiovascular and respiratory dysfunction 1, 3

Young children (<6 years) may present with nonspecific or atypical clinical features such as poorly localized pain, refusal to bear weight, irritability, meningism, or unsteady gait, which can delay diagnosis 5

About 80% of patients regain walking ability at 6 months after disease onset 2
Recovery can continue for more than 3 years after onset 6
Recurrence of GBS is rare (2-5%) 6
Regular follow-up is necessary to monitor for long-term complications and ensure complete recovery 1